Viatris Inc

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Canonsburg, Pennsylvania

Most recent report

10-Q, filed Nov 5, 2026

Incorporated

Delaware

Filings on record

545 filings

On EDGAR

CIK 1792044

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 4 of 9 sections worth reading, with 1 positive, 12 notable, and 7 negative flags.

• Part I

  Financial statements show net loss, debt maturity wall, and a pending $1.65B acquisition.
  Notable

  • Agreed to acquire Pacira for $1.65B cash, funded from excess cash and short-term borrowings.
  • Sold Biocon Biologics equity for ~$380M in July 2026; recognized $36M pre-tax loss on the stake.
  • Issued €650M 4.25% Senior Notes due 2033 to refinance $1.675B 2026 notes.
  • Restructuring program expects $700M-$850M in charges; $157.3M recorded in first nine months of 2026.
  Negative

  • Nashik facility received OAI classification; voluntary suspension of manufacturing until Q1 2027.
  • Opioid settlement finalized at up to $335M; $281.3M accrued as of September 30, 2026.

• Management's Discussion (Item 2)

  Contains detailed segment results, restructuring costs, manufacturing disruptions, and a pending acquisition.
  Positive

  • Adjusted gross margin improved to 58% in Q3 2026 from 56% in Q3 2025, driven by higher-margin product mix.
  Notable

  • FDA warning letter and import alert at Indore facility remain; 11 products barred from U.S. until lifted.
  • Share repurchases slowed to $150M in Q3 2026 from $67.9M in Q3 2025; $300M year-to-date vs $418.3M last year.
  • Top 10 products represented 41% of net sales in Q3 2026, up from 38% in Q3 2025, indicating increased concentration.
  • Greater China net sales grew 14% in Q3 2026 (10% constant currency), driven by strong e-commerce and retail growth.
  • Cash from operations was $1.67B for nine months ended Sep 2026, up from $1.50B in prior year; cash balance $1.79B.
  • Accrued $459M for legal contingencies at September 30, 2026.
  Negative

  • Nashik facility fire and FDA OAI classification expected to reduce Q4 2026 revenues by ~$100M; production suspended.

• Controls and Procedures (Item 4)

  New ERP system implementation creates ICFR risks through year-end 2026.
  Notable

  • New ERP system for non-U.S. entities implemented in Q3 2026, with risks to ICFR through year-end.
  • Company will continue modifying internal controls and testing through end of calendar year 2026.

• Risk Factors (Item 1A)

  New risk: proposed Pacira acquisition may fail or underperform, with specific conditions and consequences.
  Negative

  • Acquisition of Pacira may not complete due to conditions like tender threshold and antitrust; failure could materially hurt results.
  • Conditions include at least one share more than 50% of Pacira shares tendered; no assurance of satisfaction.
  • Failure to integrate or retain talent could prevent realizing expected synergies and capabilities.
  • Failure of acquisition could materially affect business, financial condition, cash flows, dividends, share repurchases, and stock price.

What changed: Sep 2026 vs. Jun 2026

About 5% of VTRS's Sep 2026 10-Q is new information. 30 paragraphs were added, 212 changed, and 30 removed. Below are the most important lines SECSift identified.

• Item 2 94
• Part I 80
• Item 4 3
• Item 1A 3
• Item 1 1
• Item 5 1